Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nadifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonadifloxacin SCHEMBL36594 | 1.00 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL3818938 | 1.00 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL29429713 | 1.00 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL29390463 | 1.00 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL3972618 | 0.99 | LMNA (0.98) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL3973065 | 0.99 | LMNA (0.98) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL28112583 | 0.96 | LMNA (0.93) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL10994613 | 0.93 | LMNA (0.87) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL16518627 | 0.92 | LMNA (0.85) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL11185046 | 0.92 | LMNA (0.85) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5026 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| CN-122017096-A | Resolution detection method of nadifloxacin enantiomer | 江西省药品检验检测研究院 | 2026-05-12 | — | — | CN | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260027255-A1 | Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same | BETTY YU SKIN TECH ADVISORS LLC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4658376-A1 | SKIN CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250360153-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACNE | LEE SEUNG CHANG (KR) | 2025-11-27 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000006122-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED TASTE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-10 | — | — | WO | claimed |
| EP-0688218-B1 | INTERLEUKIN-1 INHIBITOR | OTSUKA PHARMA CO LTD (JP) | 1999-11-17 | — | — | EP | claimed |
| EP-0908181-A1 | REMEDY FOR ROSACEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-14 | — | — | EP | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| CN-1179940-A | Method for preparation of medicinal aerosol | WANG SHILI (CN) | 1998-04-29 | — | — | CN | claimed |
| EP-0688218-A1 | INTERLEUKIN-1 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-27 | — | — | EP | claimed |
| WO-1994020105-A1 | INTERLEUKIN-1 INHIBITOR | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-09-15 | — | — | WO | claimed |
| US-4399134-A | BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-08-16 | — | — | US | claimed |